Sikic BI - Search Results

1

Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.

Yahanda AM, Alder KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BI. Yahanda AM, et al. Among authors: sikic bi. J Clin Oncol. 1992 Oct;10(10):1624-34. doi: 10.1200/JCO.1992.10.10.1624. J Clin Oncol. 1992. PMID: 1403040 Clinical Trial.

2

Modification of cisplatin toxicity with diethyldithiocarbamate.

Berry JM, Jacobs C, Sikic B, Halsey J, Borch RF. Berry JM, et al. J Clin Oncol. 1990 Sep;8(9):1585-90. doi: 10.1200/JCO.1990.8.9.1585. J Clin Oncol. 1990. PMID: 2167955

3

A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer.

Fisher GA, Kuo T, Ramsey M, Schwartz E, Rouse RV, Cho CD, Halsey J, Sikic BI. Fisher GA, et al. Among authors: sikic bi. Clin Cancer Res. 2008 Nov 1;14(21):7074-9. doi: 10.1158/1078-0432.CCR-08-1014. Clin Cancer Res. 2008. PMID: 18981005 Free PMC article. Clinical Trial.

4

Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.

Advani R, Fisher GA, Lum BL, Jambalos C, Cho CD, Cohen M, Gollerkeri A, Sikic BI. Advani R, et al. Among authors: sikic bi. Clin Cancer Res. 2003 Nov 1;9(14):5187-94. Clin Cancer Res. 2003. PMID: 14613998 Clinical Trial.

5

Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.

Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI. Kuo T, et al. Among authors: sikic bi. J Clin Oncol. 2005 Aug 20;23(24):5613-9. doi: 10.1200/JCO.2005.08.359. J Clin Oncol. 2005. PMID: 16110021 Clinical Trial.

6

Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.

Cho CD, Fisher GA, Halsey J, Sikic BI. Cho CD, et al. Among authors: sikic bi. Invest New Drugs. 2006 Mar;24(2):117-23. doi: 10.1007/s10637-006-2032-7. Invest New Drugs. 2006. PMID: 16683204 Clinical Trial.

7

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI. Lum BL, et al. Among authors: sikic bi. J Clin Oncol. 1992 Oct;10(10):1635-42. doi: 10.1200/JCO.1992.10.10.1635. J Clin Oncol. 1992. PMID: 1403041 Clinical Trial.

8

Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells.

Gosland MP, Lum BL, Sikic BI. Gosland MP, et al. Among authors: sikic bi. Cancer Res. 1989 Dec 15;49(24 Pt 1):6901-5. Cancer Res. 1989. PMID: 2582432

9

Clinical studies with modulators of multidrug resistance.

Fisher GA, Sikic BI. Fisher GA, et al. Among authors: sikic bi. Hematol Oncol Clin North Am. 1995 Apr;9(2):363-82. Hematol Oncol Clin North Am. 1995. PMID: 7642468 Review.

10

Clinical reversal of multidrug resistance.

Sikic BI, Fisher GA, Lum BL, Brophy NA, Yahanda AM, Adler KM, Halsey J. Sikic BI, et al. Cancer Treat Res. 1994;73:149-65. doi: 10.1007/978-1-4615-2632-2_8. Cancer Treat Res. 1994. PMID: 7710904 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

207 results

Search Page

Filters